Hardman Talks | Survival of the life sciences sector

In this Hardman Talks, Keith Hiscock sits down with Dr Martin Hall, Head of Life Sciences at Hardman & Co.
2023 was a difficult year for small life sciences companies (pharmaceutical, biotech, medtech, diagnostics, healthcare), largely because it was apparent that several companies were in need of additional working capital, causing share prices to be marked down in anticipation of equity raises. 2024 has started much the same. At the time of writing, 21 companies have announced capital increases, raising £174m, and there are at least 10 other companies known to be in need of cash over the coming months.
It is well known that this is a capital intensive industry, so what has changed? When Martin started as an analyst 36 years ago, there were many more institutional investors and nearly all had either a specialist healthcare team or a specialist small cap team. Extensive consolidation within the investment community, increased regulation and risk assessment within pension funds, and a vast increase in wealth being invested has resulted in a small number of groups with enormous funds under management. Consequently, their interest in small cap companies has evaporated, preferring to use alternative investment funds for their exposure to this space. Only a handful of institutional investors still have specialist healthcare analysts, so when a small cap healthcare company needs a capital increase, its options with the institutional investors are very limited.
As a result, companies have sought alternative sources of funding, which has often resulted in a disaster for existing shareholders. Companies have undergone a trade sale at a minimal valuation, delisted and returned to private hands, moved their listings to US, or, sadly, gone bust. Small life science companies desperately need more support. Unless there is a significant change within UK institutional investors, the life sciences sector will disappear.
Watch the interview now to find out more about the sector, and read the report for free on our website: hardmanandco.c...
Important notice:
This content has been prepared purely for information purposes, and should not be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The companies or legal entities covered in this content may or may not pay us a fixed fee for this content to be made available.
Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment, and the securities or legal entities mentioned in this content may not be suitable or appropriate for all investors. Each investor’s particular needs, investment objectives and financial situation were not taken into account in the preparation of this content. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this content various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.
For more information, please read our full disclaimers:
www.hardmanandco.com/research-disclosures
www.hardmanandco.com/disclaimer